TOPICS
| Ronald Klein, USA |
Epidemiology |
| Tom Williamson, UK |
Haemodynamics |
| Charles Esmon, USA |
Ophthalmology
and thrombosis |
| Jean-Luc Wautier, France |
Red blood
cells |
| Phillip G. de Groot, Netherlands
|
Antiphospholipid
syndrome |
| Steven Lentz, USA |
Hyperhomocysteinaemia |
| Thaddeus Dryja, USA |
Molecular
genetics |
| Ingrid Pabinger, Austria |
Medical treatment |
| Jeff Heier, USA |
Anti-VEGF
therapy |
| Baruch D. Kuppermann, USA |
Intravitreal
steroids |
| Mark Blumenkranz, USA |
Rapamycin
and mTor Inhibition |
| Daniel Finkelstein, USA |
Laser treatment |
| Jose Garcia-Arumi, Spain |
Surgical approach |
FINAL PROGRAM
Retinal
vascular diseases
Stand: 2007.10.08 |
08:15 URSULA SCHMIDT-ERFURTH MD
Welcome
SESSION
1:
EPIDEMIOLOGY / VASCULAR BIOLOGY
Chair: Ronald Klein
MD, Ingrid Pabinger MD |
08:30 Ronald Klein MD
University of Wisconsin School of Medicine and Public Health, Madison,
Wisconsin, USA
Epidemiology of retinal vein occlusion
09:00 Tom Williamson MD
St. Thomas Hospital, London, UK
Haemodynamic particularities of retinal blood vessels: the "throttle"
mechanism and arterial shear
stress in the retinal vein
09:30 Charles Esmon PhD
Howard Hughes Medical Institute and the Oklahoma Medical Research
Foundation, Oklahoma
City, Oklahoma, USA
Bringing ophthalmology and thrombosis together
10:00 Jean-Luc Wautier MD PhD
University Diderot Paris and Institut National de la Transfusion
Sanguine, Paris, France
Red blood cells in vascular disease - Red cells: the culprit of retinal
vein occlusion?
10:30 Coffee break
SESSION
2:
SELECTED RISK FACTORS/ POTENTIAL RELEVANCE
Chair: Thaddeus Dryja
MD, Charles Esmon PhD |
11:00 Philip G. de Groot MD
University Medical Center, Department of Clinical Chemistry and
Haematology, Utrecht, The
Netherlands
The antiphospholipid syndrome
11:30 Steven R. Lentz MD PhD
University of Iowa, Iowa City, Iowa, USA
Mechanism of homocysteine-induced atherothrombosis
12:00 Thaddeus Dryja MD
Translational Medicine in Ophthalmology and Molecular Genetics,
Novartis Institutes of Biomedical Research
Cambridge, Massachusetts, USA
Molecular genetics of retinal vascular diseases
12:30 Lunch
SESSION
3:
CURRENT TREATMENT OPTIONS:
HAEMATOLOGY, VASCULAR ENDOTHELIAL GROWTH FACTOR AND STEROIDS
Chair:
Ursula Schmidt-Erfurth MD, Mark Blumenkranz MD |
13:30 Ingrid Pabinger MD
Department of Internal Medicine, Medical University Vienna, Austria
Retinal vascular disease: Therapeutic approaches from a haematological
point of view
14:00 Jeffrey S. Heier MD
Tufts University School of Medicine, Medford, Massachusetts, USA
and Harvard Medical School,
Boston, Massachusetts, USA
Anti-VEGF Therapy in the Treatment of Retinal Venous Occlusive Disease
14:30 Baruch D. Kuppermann MD PhD
Department of Ophthalmology, University of California, Irvine,
California, USA
The role of intravitreal steroids and implants in the management of
retinal vein occlusions
15:00 Mark S. Blumenkranz MD
Stanford University, California, USA
RAPAMYCIN (Sirolimus) The use of mTOR inhibition is a treatment for
retinal vascular disease
associated with proliferation and hyperpermeability
15:30 Coffee break
SESSION
4:
CURRENT TREATMENT OPTIONS:
LASER, SURGERY
Chair: Baruch D. Kuppermann
MD PhD, Jeffrey S. Heier MD |
16:00 Daniel Finkelstein MD
The Wilmer Ophthalmological Institute, The Johns Hopkins Hospital,
Baltimore, Maryland, USA
The role of Laser Treatment in Retinal Vein Occlusion
16:30 Jose Garcia-Arumi MD
Institut de Recerca Hospital Universitari Vall D’Hebron, Barcelona,
Spain
Retinal vascular occlusion: the surgical approach
SESSION
5:
PANEL DISCUSSION
17:00 - 18:00 |
|
(PDF 16KB)